Trade Gilead ^GILD

BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Gilead Sciences (GILD) Set to Post Quarterly Earnings on Thursday

Gilead Sciences, Inc. $GILD Stock Sold by Crossmark Global Holdings Inc. - Stock Observer

Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Reduces Stake

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Target Price of $159.63

Gilead Sciences, Inc. $GILD Stock Sold by Nisa Investment Advisors LLC

Gilead's Emvistegrast Pill Shows Promising Results in Clinical Trial for Ulcerative Colitis, ETPharma

Gilead Sciences, Inc. $GILD Stock: Range Financial Group LLC Boosts Holdings - Daily Political

Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Trims Stake - Daily Political

Biotech Stocks To Keep An Eye On - October 18th - Stock Observer

Population-level impact of doxycycline post-exposure prophylaxis on bacterial sexually transmitted infections

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Bank of America Analyst Says - Zolmax

Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Bank of America

15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC

How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals

Gilead Sciences, Inc. $GILD Holdings Decreased by Foundation Resource Management Inc. - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Foundation Resource Management Inc. - Daily Political

43 ETFs Add to Gilead Sciences (GILD) on Thursday

Gilead's pill succeeds in mid-stage bowel disease trial

Rare prostate cancer histologies: detection, characteristics and treatment

Best Medical Stocks To Consider - October 18th - Markets Daily

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? - AOL

Gilead Sciences, Inc. $GILD Stake Cut by TD Waterhouse Canada Inc.

Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative? - Simply Wall St News

Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.

Promising Medical Stocks To Research - October 14th

Cognizant Technology Solutions (CTSH) Is Back In The Spotlight, What Is Drawing Attention?

Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Stock

Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Company Stock

What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?

Ninety One UK Ltd Buys New Shares in Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Shares Climb 3.9% - Time to Buy? - Stock Observer

Gilead Sciences, Inc. $GILD Stake Trimmed by Curated Wealth Partners LLC - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC

Gilead Sciences Inc. (GILD) - Insider Monkey

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets | Morningstar

Gilead Sciences On Track for Record High Close - Data Talk | Morningstar

Case: Trademarks/Injunctions (4th Cir.)

Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma

Stock Market Movers: Best and Worst Performers of 14 October 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Up 3.9% - What's Next?

Vir partners with Gilead in $1.8B+ deal for T-cell engagers

Verastem focuses on KRAS G12D therapy, reports 41% ORR in PDAC

Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs

Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | Morningstar

Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC

Promising Pharmaceutical Stocks To Follow Now - October 11th - Markets Daily

Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co. - Daily Political

Fagan Associates Inc. Buys New Stake in Gilead Sciences, Inc. $GILD

Erste Group Bank Comments on Gilead Sciences FY2027 Earnings

44,466 Gilead Sciences, Inc. $GILD Shares Sold by CoreCap Advisors LLC

Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?

Biotech Stocks To Watch Today - October 11th - Daily Political

Can Gilead (GILD) Stock Continue Rising in 2027?

Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?

Promising Pharmaceutical Stocks To Follow Now - October 11th - Daily Political

Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?

Top Biotech Stocks To Watch Now - October 10th - Markets Daily

Medical Stocks To Follow Now - October 10th - Daily Political

Gilead Sciences (GILD) Could Be Trading At A 18% Premium Following Strong Earnings

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00 - Daily Political

Medical Stocks To Research - October 9th - Stock Observer

What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?

Gilead Sciences' (GILD) Overweight Rating Reaffirmed at Cantor Fitzgerald - Stock Observer

Gilead Sciences (NASDAQ:GILD) Given Overweight Rating at Cantor Fitzgerald - Stock Observer

Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - Stock Observer

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Daily Political

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co.

GILD Maintained by Morgan Stanley -- Price Target Lowered to $16

Morgan Stanley Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $163.00

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - Stock Observer

Nurix Extends Gilead Oncology Research Collaboration For Two Years

Zacks Research Lowers Earnings Estimates for Gilead Sciences

Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan - Zolmax

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional

Biotech Stocks To Watch Now - October 2nd - Daily Political

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Biotech Stocks To Watch Now - October 2nd - Zolmax

Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 Shares - Daily Political

Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD

HIV prevention drug hailed as breakthrough, but who gets access?

Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research

Zacks Research Downgrades Gilead Sciences (NASDAQ:GILD) to Hold - Stock Observer

GILD: HIV Growth Still Leads, Oncology And Immunology Now Carry More Weight

Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire

Best Medical Stocks To Watch Today - September 29th - Markets Daily

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?